Singapore markets closed
  • Straits Times Index

    3,013.85
    -0.93 (-0.03%)
     
  • Nikkei

    28,864.32
    -65.79 (-0.23%)
     
  • Hang Seng

    29,098.29
    -138.50 (-0.47%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • BTC-USD

    48,096.25
    -1,801.94 (-3.61%)
     
  • CMC Crypto 200

    962.34
    +19.16 (+2.03%)
     
  • S&P 500

    3,794.84
    +26.37 (+0.70%)
     
  • Dow

    31,155.59
    +231.45 (+0.75%)
     
  • Nasdaq

    12,739.04
    +15.57 (+0.12%)
     
  • Gold

    1,698.70
    -2.00 (-0.12%)
     
  • Crude Oil

    66.08
    +2.25 (+3.52%)
     
  • 10-Yr Bond

    1.5610
    +0.0110 (+0.71%)
     
  • FTSE Bursa Malaysia

    1,600.12
    +18.86 (+1.19%)
     
  • Jakarta Composite Index

    6,258.75
    -32.05 (-0.51%)
     
  • PSE Index

    6,881.37
    -1.12 (-0.02%)
     

J&J strikes deal with Emergent BioSolutions on coronavirus vaccine manufacturing

·1-min read
FILE PHOTO: The company logo for Johnson & Johnson is displayed to celebrate the 75th anniversary of the company's listing at the NYSE in New York

(Reuters) - Johnson & Johnson said on Thursday it had struck a deal with Emergent BioSolutions Inc to use its manufacturing facilities to help in an effort to make more than 1 billion doses of a vaccine it is testing to stop the novel coronavirus.

The U.S. healthcare conglomerate said the deal was the first in a series of prospective global partnerships to accelerate manufacturing of its experimental COVID-19 vaccine candidate, even before it has a signal that it works.

J&J plans to start human testing by September, with an eye on having it ready under an emergency use authorization in early 2021, far quicker than the typical 18-month period that it takes for vaccines to be tested, approved and then manufactured.

Under the deal, valued at about $135 million, Emergent said it would provide drug substance manufacturing services and was reserving large-scale manufacturing capacity.

J&J and the U.S. government are investing $1 billion to create enough manufacturing capacity for the experimental vaccine candidate to stop the virus that has killed nearly 185,000 people around the globe.

(Reporting by Uday Sampath in Bengaluru; Editing by Subhranshu Sahu)